Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytosorbents (CTSO) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to -$0.05.

  • Cytosorbents' EPS (Basic) changed 0.0% to -$0.05 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.18, marking a year-over-year increase of 5000.0%. This contributed to the annual value of -$0.38 for FY2024, which is 4144.29% up from last year.
  • Cytosorbents' EPS (Basic) amounted to -$0.05 in Q3 2025, which was down 0.0% from $0.03 recorded in Q2 2025.
  • Cytosorbents' 5-year EPS (Basic) high stood at $0.03 for Q2 2025, and its period low was -$0.28 during Q3 2022.
  • For the 5-year period, Cytosorbents' EPS (Basic) averaged around -$0.13, with its median value being -$0.13 (2023).
  • As far as peak fluctuations go, Cytosorbents' EPS (Basic) plummeted by 133196.16% in 2021, and later soared by 13750.0% in 2025.
  • Over the past 5 years, Cytosorbents' EPS (Basic) (Quarter) stood at -$0.25 in 2021, then skyrocketed by 92.97% to -$0.02 in 2022, then crashed by 643.14% to -$0.13 in 2023, then decreased by 6.39% to -$0.14 in 2024, then skyrocketed by 64.03% to -$0.05 in 2025.
  • Its EPS (Basic) was -$0.05 in Q3 2025, compared to $0.03 in Q2 2025 and -$0.02 in Q1 2025.